» Articles » PMID: 22438271

Adeno-associated Virus-delivered Polycistronic MicroRNA-clusters for Knockdown of Vascular Endothelial Growth Factor in Vivo

Abstract

Background: Vascular endothelial growth factor (VEGF) is an angiogenic growth factor that plays a critical role in several diseases, including cancer, rheumatoid arthritis and diseases of the eye. Persistent regulation of VEGF by expression of small interfering RNAs targeting VEGF represents a potential future strategy for treatment of such diseases. As a step toward this goal, the present study combines the potency of VEGF-targeted miRNA mimics, produced from a miRNA cluster, with delivery by adeno-associated virus (AAV)-based vectors.

Methods: Nine different engineered tri-cistronic miRNA clusters encoding anti-VEGF effectors were generated and tested in adult human retinal pigment epithelial (ARPE-19) cells using Renilla luciferase screening, quantitative reverse transcriptase-polymerase chain reaction (RT-PCR), western blotting and immunostaining analysis. In vivo efficacy was tested by the injection of scAAV2/8 vectors expressing the most effective miRNA cluster into murine hindlimb muscles, followed by quantitative RT-PCR.

Results: Plasmids containing anti-VEGF miRNA clusters showed efficient silencing of VEGF and demonstrated a combined gene silencing effect for miRNA clusters composed of multiple miRNA-mimicked RNA interference effectors. The most potent molecule, miR-5,10,7, resulted in a knockdown of VEGF by approximately 75%. Injection of scAAV2/8 vectors expressing miR-5,10,7 into murine hindlimb muscles, resulted in a 44% reduction of endogenous VEGF.

Conclusions: We have developed miRNA clusters encoding anti-VEGF effectors and shown, in a mouse model, that VEGF is efficiently down-regulated by scAAV2/8-delivered miRNA clusters, allowing potent attenuation of VEGF. These findings may contribute to the development of gene therapy based on AAV-mediated delivery of miRNA clusters.

Citing Articles

Engineered lentivirus-derived nanoparticles (LVNPs) for delivery of CRISPR/Cas ribonucleoprotein complexes supporting base editing, prime editing and in vivo gene modification.

Haldrup J, Andersen S, Labial A, Wolff J, Frandsen F, Skov T Nucleic Acids Res. 2023; 51(18):10059-10074.

PMID: 37678882 PMC: 10570023. DOI: 10.1093/nar/gkad676.


Mirtron-mediated RNA knockdown/replacement therapy for the treatment of dominant retinitis pigmentosa.

Orlans H, McClements M, Barnard A, de la Camara C, MacLaren R Nat Commun. 2021; 12(1):4934.

PMID: 34400638 PMC: 8368061. DOI: 10.1038/s41467-021-25204-3.


Alterations of Growth and Focal Adhesion Molecules in Human Breast Cancer Cells Exposed to the Random Positioning Machine.

Sahana J, Corydon T, Wehland M, Kruger M, Kopp S, Melnik D Front Cell Dev Biol. 2021; 9:672098.

PMID: 34277614 PMC: 8278480. DOI: 10.3389/fcell.2021.672098.


An Analysis of Mechanisms for Cellular Uptake of miRNAs to Enhance Drug Delivery and Efficacy in Cancer Chemoresistance.

Grixti J, Ayers D, Day P Noncoding RNA. 2021; 7(2).

PMID: 33923485 PMC: 8167612. DOI: 10.3390/ncrna7020027.


MicroRNAs in laser-induced choroidal neovascularization in mice and rats: their expression and potential therapeutic targets.

Martinez B, Peplow P Neural Regen Res. 2020; 16(4):621-627.

PMID: 33063711 PMC: 8067925. DOI: 10.4103/1673-5374.295271.